IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
29.15
-0.32 (-1.09%)
Jun 1, 2026, 1:44 PM EDT - Market open
IDEAYA Biosciences Revenue
IDEAYA Biosciences had revenue of $6.56M in the quarter ending March 31, 2026. This brings the company's revenue in the last twelve months to $225.27M, up 3,118.14% year-over-year. In the year 2025, IDEAYA Biosciences had annual revenue of $218.71M with 3,024.43% growth.
Revenue (ttm)
$225.27M
Revenue Growth
+3,118.14%
P/S Ratio
11.27
Revenue / Employee
$1,553,586
Employees
145
Market Cap
2.56B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 218.71M | 211.71M | 3,024.43% |
| Dec 31, 2024 | 7.00M | -16.39M | -70.07% |
| Dec 31, 2023 | 23.39M | -27.55M | -54.08% |
| Dec 31, 2022 | 50.93M | 22.99M | 82.28% |
| Dec 31, 2021 | 27.94M | 8.40M | 43.01% |
| Dec 31, 2020 | 19.54M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Tarsus Pharmaceuticals | 535.08M |
| Arcutis Biotherapeutics | 415.62M |
| Alumis | 8.40M |
| Immunome | 4.02M |
| Celldex Therapeutics | 865.00K |
IDYA News
- 2 hours ago - IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO - PRNewsWire
- 3 days ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 5 days ago - Ideaya Biosciences management to meet with Cantor - TheFly
- 6 days ago - IDEAYA Biosciences Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Transcripts
- 6 days ago - IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference - PRNewsWire
- 13 days ago - IDEAYA Biosciences Transcript: Stifel 2026 Targeted Oncology Virtual Forum - Transcripts
- 19 days ago - IDEAYA Biosciences Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 25 days ago - Ideaya Biosciences price target lowered to $50 from $52 at Mizuho - TheFly